Literature DB >> 17825252

Cephalochromin, a FabI-directed antibacterial of microbial origin.

Chang Ji Zheng1, Mi-Jin Sohn, Sangku Lee, Young-Soo Hong, Jin-Hwan Kwak, Won-Gon Kim.   

Abstract

Microorganisms produce many kinds of antibiotics which function in an antagonistic capacity in nature where they have much competition. Bacterial enoyl-acyl carrier protein (ACP) reductase (FabI) has been demonstrated to be an antibacterial target. However, no FabI-directed antibiotic of microbial origin has been reported so far. In this study, we found that cephalochromin with a naphtho-gamma-pyrone skeleton, a fungal secondary metabolite, inhibited FabI of Staphylococcus aureus and Escherichia coli with IC50 of 1.9 and 1.8 microM, respectively. The methylether derivatives of cephalochromin, however, did not inhibit FabI. The FabI-inhibitory activities of cephalochromin and its derivatives well correlated with antibacterial activity as well as the inhibition of cellular fatty acid biosynthesis. Furthermore, FabI-overexpressing S. aureus exhibited reduced susceptibility to cephalochromin compared to the wild-type strain, demonstrating that the mode of antibacterial action of cephalochromin is via the inhibition of FabI. These results indicate that cephalochromin is the first FabI-directed antibacterial of microbial origin and may have the potential for further antibacterial development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825252     DOI: 10.1016/j.bbrc.2007.08.144

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?

Authors:  Joshua B Parsons; Charles O Rock
Journal:  Curr Opin Microbiol       Date:  2011-08-20       Impact factor: 7.934

2.  Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.

Authors:  Joshua B Parsons; Matthew W Frank; Chitra Subramanian; Panatda Saenkham; Charles O Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

Review 3.  Using modern tools to probe the structure-function relationship of fatty acid synthases.

Authors:  Kara Finzel; D John Lee; Michael D Burkart
Journal:  Chembiochem       Date:  2015-02-10       Impact factor: 3.164

Review 4.  Mining Fatty Acid Biosynthesis for New Antimicrobials.

Authors:  Christopher D Radka; Charles O Rock
Journal:  Annu Rev Microbiol       Date:  2022-06-01       Impact factor: 16.232

Review 5.  Bacterial Enoyl-Reductases: The Ever-Growing List of Fabs, Their Mechanisms and Inhibition.

Authors:  Fernanda S M Hopf; Candida D Roth; Eduardo V de Souza; Luiza Galina; Alexia M Czeczot; Pablo Machado; Luiz A Basso; Cristiano V Bizarro
Journal:  Front Microbiol       Date:  2022-06-16       Impact factor: 6.064

6.  Bacterial fatty acid synthesis and its relationships with polyketide synthetic pathways.

Authors:  John E Cronan; Jacob Thomas
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 7.  Diversity in enoyl-acyl carrier protein reductases.

Authors:  R P Massengo-Tiassé; J E Cronan
Journal:  Cell Mol Life Sci       Date:  2009-05       Impact factor: 9.261

8.  Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.

Authors:  Chang Ji Zheng; Mi-Jin Sohn; Sangku Lee; Won-Gon Kim
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

9.  Fungal naphtho-γ-pyrones: Potent antibiotics for drug-resistant microbial pathogens.

Authors:  Yan He; Jun Tian; Xintao Chen; Weiguang Sun; Hucheng Zhu; Qin Li; Liang Lei; Guangmin Yao; Yongbo Xue; Jianping Wang; Hua Li; Yonghui Zhang
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

10.  Induction of Isochromanones by Co-Cultivation of the Marine Fungus Cosmospora sp. and the Phytopathogen Magnaporthe oryzae.

Authors:  Ernest Oppong-Danquah; Martina Blümel; Silvia Scarpato; Alfonso Mangoni; Deniz Tasdemir
Journal:  Int J Mol Sci       Date:  2022-01-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.